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A B S T R A C T
Hemophilia B (HB) is a life-threatening inherited disease caused by mutations in the FIX gene, leading to reduced
protein function and abnormal blood clotting. Due to its monogenic nature, HB is one of the primary targets for
gene therapy. Indeed, successful correction of HB has been shown in clinical trials using gene therapy ap-
proaches. However, application of these strategies to non-adult patients is limited due to high cell turnover as
young patients develop, resulting in vector dilution and subsequent loss of therapeutic expression. Gene editing
can potentially overcome this issue by permanently inserting the corrective gene. Integration allows replication
of the therapeutic transgene at every cell division and can avoid issues associated with vector dilution. In this
study, we explored adenovirus as a platform for corrective CRISPR/Cas9-mediated gene knock-in. We de-
termined as a proof-of-principle that adenoviral delivery of CRISPR/Cas9 is capable of corrective gene addition,
leading to long-term augmentation of FIX activity and phenotypic correction in a murine model of juvenile HB.
While we found on-target error-free integration in all examined samples, some mice also contained mutations at
the integration target site. Additionally, we detected adaptive immune responses against the vector and Cas9
nuclease. Overall, our ﬁndings show that the adenovirus platform is suitable for gene insertion in juveniles with
inherited disease, suggesting this approach may be applicable to other diseases.
1. Introduction
Recent clinical trials have shown success in treatment of inherited
genetic diseases with gene therapy owing to sustained therapeutic gene
expression. In particular, gene therapies for hemophilia B (HB) have
attained long-term disease correction in human patients using re-
combinant adeno-associated viral (rAAV) vectors [1–3]. HB is a life-
threatening inherited disease caused by mutations in the coagulation
Factor IX (FIX) gene. These mutations lead to absent or aberrant FIX
function within the blood coagulation cascade, characterized by the
inability to form proper blood clots. Due to its monogenic nature, HB is
a preeminent target for gene therapy. Although eﬀective in liver-di-
rected gene transfer for adults, current gene replacement therapies are
inadequate for application in pediatric and young patients, based upon
preclinical ﬁndings in non-adult animals [4–7]. In non-adult animal
models, gene expression decreases over time for several reasons in-
cluding vector dilution and the loss of transduced cell populations. In
non-adults, transferred episomal genes dilute from cell division during
liver growth, in contrast to quiescent adult livers [4–7]. In both adults
and non-adults the loss of transduced cell populations can also limit
therapeutic gene expression. Taken together, there remains an unmet
need for methods to attain life-long gene expression in pediatric pa-
tients. Gene editing is a promising method that may allow for the
permanent incorporation of corrective genes into the chromosomes of
young patients to overcome loss of gene expression due to vector di-
lution. Theoretically, such integration may also counteract the loss of
transduced cell populations if progenitor or stem cells genetically in-
corporate the corrective transgene and are not eliminated.
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Targetable editing-based genomic integration approaches could be
exceptionally useful for in vivo somatic therapy, with the potential to
circumvent the loss of gene expression associated with episomal per-
sistence-based vectors. Such integration allows corrective gene addition
or in situ correction of the endogenous defective gene. In this regard,
lentiviral vectors (LVs) integrate with viral integrases and have
achieved sustained gene expression in severely immunodeﬁcient pe-
diatric patients [8–9]. However, integrase-mediated integration occurs
promiscuously throughout the genome of target cells, with a preference
for transcriptionally active regions, and consequently can perturb the
surrounding genomic environment [10–13]. As such, targeting in-
tegration to a speciﬁc well-characterized locus, termed ‘safe harbor’, or
to endogenous disease loci, is highly desirable. Gene delivery methods
using rAAVs have shown targeted gene editing is a plausible strategy to
treat models of inherited diseases, including neonatal HB [14–17]. In-
deed, rAAV is currently the preferred platform for liver-directed
therapies to correct monogenic diseases, including its use in a recent
gene editing clinical trial utilizing zinc ﬁnger nucleases (ZFN) to treat
adult HB [18]. Despite such promising progress, this delivery system
has limitations. Of note, random viral integration constitutes the basis
of residual rAAV vector persistence after administration in prenatal and
neonatal animals and may thus aﬀect residual gene expression levels in
developing organisms [5,15,and 19]. Furthermore, the risk associated
with random integration of rAAV vector sequences, insertion of vector
genomes at editing target sites, and a limited packaging capacity con-
strain application of this vector in some contexts [20–22].
In contrast, the use of adenovirus vectors to mediate editing-based
integration has not been explored to the same degree as rAAVs [23–24].
Adenoviral vectors have a large packaging capacity, which may be
useful for integration of large genes or useful for elaborate gene editing
strategies [23–27]. Additionally, adenoviral vectors are capable of
highly eﬃcient cell-speciﬁc infection and do not readily integrate into
host genomes [28]. Thus, the use of adenoviral-mediated gene transfer
for editing-based integration could accomplish disease correction with
reduced genotoxic risk. Nonetheless, whether adenoviral delivery of
gene editing systems can overcome the issues which counteract long-
evity of episomal-based expression has yet to be determined. In other
words, any virally transduced cell can encounter vector silencing, im-
mune-mediated elimination, or other mechanisms (such as cell death or
high cell turnover) leading to the loss of gene expression- irrespective of
whether editing has occurred. Although we have previously shown
adenovirus-mediated gene knock-in can augment levels of a serum
protein, it remains unclear whether such approach can attain prolonged
phenotypic correction in a pediatric disease context [29].
In this study, CRISPR/Cas9 is used to mediate targeted gene in-
tegration in vivo. Brieﬂy, CRISPR/Cas9 systems use small RNAs to guide
an endonuclease to speciﬁc DNA sequences and has been applied for a
wide variety of therapeutic applications [30]. Adenoviral delivery of
CRISPR/Cas9 may have several advantages, including repair accuracy
and the size of constructs which may be delivered is greater than other
approaches [31]. Herein we explored whether adenoviral vectors could
(i) deliver CRISPR/Cas9 to mediate corrective gene knock-in at the
ROSA26 safe harbor locus, (ii) if such editing aﬀects longevity of
therapeutic gene expression in a murine model of HB, and (iii) explore
vector fate, integration characteristics, and host responses to this
strategy. Using this approach, we found a single injection of adenoviral
vectors achieved mFIX cDNA knock-in at the ROSA26 safe harbor and
long-term phenotypic correction of the HB bleeding diathesis. We de-
termined on-target integrated mFIX cDNA was detectable 245 days post-
injection (dpi) with errorless and error-containing integration events.
Although we detected adaptive immune responses to the adenoviral
vector and the Cas9 nuclease, the immunological responses described
herein did not abolish therapeutic beneﬁts provided by gene editing.
Overall, we demonstrate that adenoviral vectors are capable of targeted
gene integration and long-term correction of an inherited disease in
juvenile mice. Our ﬁndings support the use of gene editing to achieve
prolonged gene expression in pediatric patients.
2. Results
2.1. Adenoviral vector-mediated integration maintains higher levels of mFIX
protein than standard non-editing vectors in a hemophilia model
In this study, an adenoviral vector (Ad5-Cas9-gRNA) facilitates gene
delivery of the Streptococcus pyogenes (sp) Cas9 nuclease and a guide
RNA (gRNA) speciﬁc to the murine ROSA26 ‘safe harbor’, as char-
acterized in a previous study (Fig. 1) [29]. A second vector was con-
structed for this study, Ad5-EF1α-mFIX, which provides a template for
double stranded break (DSB) DNA repair (Fig. 1). Co-injection of Ad5-
Cas9-gRNA and Ad5-EF1α-mFIX targets Cas9 to ROSA26 for DSB gen-
eration and subsequent DNA repair (Fig. 2A). After systemic injection
with these vectors to facilitate gene transfer of the editing system, we
tracked mFIX protein expression in juvenile R333Q hemophilia mice.
As Ad5-EF1α-mFIX contains the exogenous EF1α promoter, some mFIX
is derived by episomal-based expression from the adenoviral genome.
To ascertain mFIX protein expression from residual episomal persis-
tence, we compared Ad5-Cas9 (a non-editing vector lacking a gRNA)
(Supplemental Fig. 1) and Ad5-EF1α-mFIX in parallel to the integra-
tion-mediating vectors Ad5-Cas9-gRNA and Ad5-EF1α-mFIX. This
comparative analysis allows exploration of whether targeted integra-
tion of mFIX aﬀects temporal expression, in the context of developing
mice.
We tail vein injected juvenile mice with equal amounts of Ad5-
EF1α-mFIX plus Ad5-Cas9-gRNA or Ad5-Cas9. Each group injection
consisted of a 3:1 mix of Ad5-EF1α-mFIX to secondary virus. Plasma
from mice was drawn one week before and after injection. Plasma di-
lutions' ELISA OD-values were greater post-injection compared to
plasma taken prior to injection, indicating successful expression, se-
cretion, and detection of mFIX (Supplemental Fig. 1). Upon conﬁrming
in vivo expression, we tracked mFIX plasma levels of injected mice for
238 days (Fig. 2B). At seven days post-injection (dpi), diﬀerences in
mFIX expression between Ad5-Cas9-gRNA and Ad5-Cas9 treated mice
were not statistically diﬀerent, supporting the concept that equal
amounts of mFIX-expressing virus were delivered to mice. Decreasing
mFIX protein expression was noted in all mice during the ﬁrst 80 days
following treatment, with a greater loss of expression in Ad5-Cas9 (non-
editing) treated mice, after which protein levels generally stabilized.
Fig. 1. A schematic of the adenoviral vectors used in this study. Ad5-EF1α-
mFIX (vector 1) expresses mFIX under control of the EF1α promoter and pro-
vides a homology-directed repair template, allowing gene knock-in. Ad5-EF1α-
mFIX consists of ~800 bp of ROSA26 homology sequences (R26) which ﬂank
the genomic target cut site, with the mFIX cDNA expression cassette between
the homology arms. Ad5-Cas9-gRNA (vector 2) expresses a ROSA26-speciﬁc
gRNA and Cas9 nuclease, to induce double-stranded breaks at the target site.
Control vectors for CRISPR/Cas9-mediated integration were vectors expressing
either Cas9 (Ad5-Cas9, vector 3) or gRNA (Ad5-gRNA, vector 4) alone.
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Moreover, from days 49 to 161, mFIX plasma levels of Ad5-Cas9-gRNA
treated mice (the mFIX knock-in group) stabilized around 700 ng/mL to
850 ng/mL (Table 1). Over the same period, control Ad5-Cas9 treated
mice (non-editing group) exhibited mFIX levels between 200 ng/mL to
350 ng/mL. An important diﬀerence between these two approaches was
highlighted by the comparison of mFIX levels in treated hemophilia
mice to normal human FIX levels (normal ~5000 ng/mL) [14]. Seven
days after a single injection, the mFIX plasma levels of all injected mice
were within the ‘mild’ hemophilia range of normal FIX levels (5.0% to
50.0%). Shortly thereafter, some mice treated with the combination of
Ad5-EF1α-mFIX and Ad5-Cas9 entered the plasma concentration range
of a ‘moderate’ hemophilia phenotype (1 to 5% normal), as early as 49
dpi (ranging from 1.9% to 17%). Indeed, the average mFIX plasma level
of this group was signiﬁcantly lower than Ad5-EF1α-mFIX and Ad5-
Cas9-gRNA knock-in treatment at all time points, excluding seven dpi,
for the entirety of the study. Of note, treatment with non-editing vectors
led to plasma mFIX levels ranging within or near ‘moderate’ hemophilia
for most of the experiment and dropped into the range of ‘severe’ he-
mophilia FIX levels (< 1.0%) by the conclusion of the experiment. This
ﬁnding represents the reported transient nature of expression from
early generation adenoviral vectors.
In total, mice treated with Ad5-Cas9-gRNA along with repair tem-
plate vector Ad5-EF1α-mFIX (the mFIX knock-in group), maintained
signiﬁcantly higher plasma concentrations of mFIX than Ad5-Cas9
(non-editing group) counterparts throughout the time-course, despite
receiving equal amount of mFIX-expressing and total virus (Fig. 2B). At
238 dpi, the ﬁnal mFIX levels in mice treated with Ad5-Cas9-gRNA
(mFIX knock-in group) averaged 419 ng/mL, representing a main-
tenance of 11% of the initial expression at seven dpi. In contrast, ﬁnal
mFIX levels in mice administered non-editing Ad5-Cas9 averaged
88.5 ng/mL, representing residual preservation of only 3.5% initial
expression. Thus, higher and prolonged therapeutic protein con-
centrations were provided by integration-mediating vectors in com-
parison to non-editing vectors, resulting in maintenance of mFIX levels
comparative to ‘mild’ hemophilia phenotypes for the entirety of the
experiment.
2.2. Treatment with integration-mediating vectors provides superior long-
term phenotypic correction compared to treatment with non-editing vectors
To assay disease correction, we performed two experiments at the
conclusion of the time-course. First, quantiﬁcation of FIX enzymatic
activity showed a signiﬁcant improvement between treatment with
Ad5-EF1α-mFIX and Ad5-Cas9-gRNA rather than with Ad5-Cas9, in
plasma samples taken 238 and 245 dpi (Fig. 3A). Results between these
two time points and blood collection sites did not show any meaningful
diﬀerences (Supplemental Fig. 2). The chromogenic-based measure-
ments of plasma FIX activity showed untreated R333Q hemophiliac
mice had nearly undetectable activity (< 1% normal). Plasma from
Ad5-Cas9 treated mice showed low residual FIX activity averaging
slightly over 1.0% normal, with a maximum of 4.1% normal activity. In
Fig. 2. Knock-in and non-editing adenoviral-based mFIX protein expression in juvenile hemophilia mice. (A) The ROSA26 locus is targeted by Ad5-Cas9-gRNA to
generate a double-stranded break (DSB). The DSB can subsequently be repaired by non-homologous end joining (NHEJ) or homology-directed repair (HDR) when a
repair template, such as Ad5-EF1α-mFIX, is present. HDR results in the insertion of the mFIX expression cassette. (B) Four-week old R333Q hemophilia mice were tail
vein injected with 7.5×1010 viral particles (VP) of Ad5-EF1α-mFIX and 2.5×1010 VP of either Ad5-Cas9-gRNA (blue) (n=9) or Ad5-Cas9 (red) (n=7), lacking a
gRNA needed for site speciﬁc editing. Plasma was drawn intermittently over a 238 day period and concentrations of mFIX determined using ELISA. The right y-axis
shows FIX activity seen in humans relative to protein levels on the left. Between 50% and 5.0% normal level is considered ‘mild’ hemophilia, 1–5% normal is the
range of ‘moderate’ hemophilia, while< 1.0% normal represents a ‘severe’ hemophilia phenotype. Mean values of groups are plotted with error bars denoting SEM.
Diﬀerences were considered signiﬁcant with p-values of< 0.05, represented by * for values 0.05 to 0.01, 0.01 and 0.001 were denoted by **, and p-values< 0.001
by ***. Statistical analysis was performed by parametric (Student's t-test or Welch's t-test depending on data variance) and non-parametric (Mann-Whitney U) testing
at individual time points. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Average mFIX plasma levels following adenoviral-mediated gene delivery. The
average plasma levels of mFIX (ng/mL), as determined by ELISA, are listed
according to days post-injection of four week-old R333Q mice with 7.5 × 1010
VP of Ad5-EF1a-mFIX and 2.5 x 1010 VP of either Ad5-Cas9 (left group, n=7)
or Ad5-Cas9-gRNA (right group, n=9). SD is standard deviation and SEM is








SD SEM Mean (ng/
mL)
SD SEM
7 2463.3 573.3 216.7 3804.4 1966.9 655.6
21 522.3 240.1 90.74 1581.9 899.8 299.9
35 354.8 224.9 85.01 1103.8 468.5 156.2
49 249.5 244.5 92.39 848.8 352.4 117.5
63 172.9 132.1 53.94 710.2 450.4 150.1
77 381.1 160.3 60.59 857.2 371.9 123.9
91 320.1 122.3 46.22 729.4 283.6 94.5
105 256.4 129.1 48.80 817.3 298.5 99.5
133 230.2 145.8 55.10 659.8 236.7 78.9
147 201.9 100.6 38.03 668.7 324.2 108.1
161 263.3 115.4 43.60 681.2 158.9 91.7
189 252.6 119.6 45.22 471.3 194.7 64.88
238 88.57 64.17 26.19 419.4 134.8 44.93
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contrast, plasma from Ad5-Cas9-gRNA treated mice averaged ~5.0%,
with a maximum of 10% normal activity.
Secondly, mice were submitted to a tail clip functional assay in
which the time for bleeding to stop, due to clotting of the injury, is
measured. The clipped tail of wild-type C57Bl/6J control mice bled for
approximately 8.0min, on average, while control untreated R333Q
hemophilia mice exhibited protracted bleeding with no signs of di-
minished blood ﬂow (Fig. 3B). After clippings, all Ad5-Cas9-gRNA
treated mice ceased bleeding within the experimental timeframe,
averaging 15.5min of bleeding (Fig. 3B) (plasma mFIX concentration
range 241–612 ng/mL). In contrast, mice treated with Ad5-Cas9 bled
signiﬁcantly longer (averaging 25.4 min) with no cessation of bleeding
in some mice (Fig. 3B) (plasma mFIX concentration range 25.0–168 ng/
mL). The controlled bleeding of Ad5-Cas9-gRNA treated mice re-
presents substantial phenotypic correction of the R333Q strain's
Fig. 3. FIX enzymatic activity in plasma samples and a bleeding assay for
functional correction of hemophilia. (A) At the end of the time course, plasma
samples from treated and untreated control mice were collected into 3.8% so-
dium citrate. Plasma dilutions were used in a chromogenic assay to measure FIX
enzymatic activity. 100% normal FIX activity was deﬁned by pooled plasma
from wild-type C57Bl/6J mice. Plasma was drawn from other C57Bl/6J
(n=10, black squares) and untreated control R333Q hemophilia mice (n=9,
gray circles). Additionally, plasma from mice treated with Ad5-EF1α-mFIX and
Ad5-Cas9-gRNA (n=9, blue triangles) or Ad5-Cas9 (n=7, red triangles)
(control lacking a gRNA) were also tested. Plasma samples from vector-treated
mice contained signiﬁcantly greater FIX activity than untreated R333Q mice (p-
value= 0.0353 for Ad5-Cas9, p-value=0.0003 for Ad5-Cas9-gRNA).
Additionally, mFIX knock-in treatment using Ad5-Cas9-gRNA signiﬁcantly in-
creased FIX activity compared to the non-editing Ad5-Cas9 treatment (p-
value= 0.0128). Data shown is from three independent tests. Error bars re-
present SEM. (B) Treated and untreated animal tails were clipped and the time
until bleeding had stopped was measured. Diﬀerences in bleed time between
R333Q control untreated and Ad5-Cas9 (non-editing) treatment were not sig-
niﬁcant (p-value= 0.0645). Bleed times diﬀered signiﬁcantly between control
untreated and Ad5-Cas9-gRNA (mFIX knock-in) treated mice (p-
value≤ 0.0001). Ad5-Cas9-gRNA treated mice also bled signiﬁcantly less than
Ad5-Cas9 treated mice (p-value= 0.0013). (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 4. On-target mFIX cDNA integration at ROSA26. (A) A schematic showing a
ROSA26 allele containing the integrated mFIX expression cassette. Junction
capture PCR ampliﬁes the 3′-end of ROSA26 integrated with the mFIX cDNA
using a primer set binding in the 3′-end of mFIX (black half-arrow, 5′ insert
primer) and binding downstream of the target insertion site in the genome
(black half-arrow, 3′ genomic primer), past the homology arm. (B) Junction
capture PCR reactions were performed using liver extracted genomic DNA from
mice at 245 dpi and reactions ran on an agarose gel. mFIX cDNA integrated at
ROSA26 was determined by successful ampliﬁcation of the expected full-length
1.5-kb amplicon (blue arrow), seen in Ad5-Cas9-gRNA treated mice's samples
only. Additional amplicons were randomly generated in some animals treated
with Ad5-Cas-gRNA, as seen in lane 7, representing on-target but indel-con-
taining insertions (red arrows). Amplicons were gel extracted and Sanger se-
quenced to conﬁrm identity. Ampliﬁcation of a 0.62-kb sequence of the ade-
noviral capsid gene hexon was used as a loading control and viral infection
control. Each lane represents an individual mouse's DNA as template for PCR.
Kb stands for kilo-base and M for marker. Gel is representative of four replicate
PCR and gels. (C) Liver DNA extracted at 245 dpi was used to quantify mFIX
(left) and hexon (right) copy numbers normalized to m-Actin using qPCR. Each
dot represents data from one animal and results are averaged from two in-
dependent experiments. Statistics were performed using non-parametric Mann-
Whitney U tests for non-normally distributed data. p-values are p=0.0127 for
the mFIX qPCR and p=0.2238 for the hexon qPCR. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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bleeding diathesis, which was not robustly achieved using non-editing
Ad5-Cas9. Taken together, results obtained from the ELISA time-course,
tail clips, and the enzymatic assay demonstrate that treatment with
integration-mediating vectors provides improved phenotypic correction
and greater therapeutic value than non-editing vector treatment, in the
context of juvenile mice.
2.3. Ad5-Cas9-gRNA treatment results in long-term mFIX cDNA integration
at ROSA26, in errorless and error-containing on-target conﬁgurations, and
increases mFIX copy number
To explore if gene editing occurred in treated mice, and if such
editing was still detectable at the end of the time course, liver genomic
DNA was used for junction capture PCR. PCR amplicons representing
the 3′-junction of mFIX cDNA integrated ROSA26 alleles were detected
in the genomes of mice treated with Ad-Cas9-gRNA, but not in any
untreated or Ad5-Cas9 treated mice (Fig. 4A and B). In Ad5-Cas9-gRNA
treated mice, the presence of a full-sized 1.5 kb amplicon established
that homology-directed repair (HDR) of DSBs resulted in on-target in-
tegration with Ad5-EF1α-mFIX as the repair template. Sanger sequen-
cing of the amplicon veriﬁed correct ampliﬁcation, genomic origin, and
error-free insertion of mFIX cDNA at ROSA26 (Supplemental Fig. 3).
Unexpectedly, random ampliﬁcation of smaller sized alleles were also
noted in several mice, albeit less frequently than the full-length am-
plicon (Fig. 4). Sanger sequencing of these lower MW amplicons from
one mouse revealed the presence of on-target but error-containing
‘scarred’ insertions (Supplemental Fig. 4). Several sizable deletions
(109, 209, and 584 bp) were identiﬁed at the homology border de-
monstrating that mFIX also integrated through error-prone mechanisms
(Supplemental Figs. 5–7). The insertion or deletions (indels) of nu-
cleotides only occurred in regions directly adjacent or part of the
homology border region. Interestingly, none of the three identiﬁed
error-containing alleles had mutations within the coding region of
mFIX. However, one allele contained a potential 2-bp loss at the end of
the poly(A) regulatory sequence (Supplementary Fig. 5). An insertion
(+1 bp) at the deletion break point was identiﬁed in one allele (Sup-
plemental Fig. 6). In two alleles, deletions occurred with shared bp(s) at
the break point (Supplemental Fig. 5 and 7). Overall, these data show
that (i) error-free and scarred on-target gene knock-in can occur and (ii)
editing of the ROSA26 locus is still detectable up to 245 dpi. Im-
portantly, the individual mouse with these identiﬁed indels at the on-
target integration site expressed mFIX throughout the experimental
period. The presence of these integrated alleles also demonstrates that
gene editing with an adenovirus vector permits large (4.5 kilobase (kb))
cDNA targeted knock-in and persists for a substantial time in vivo, likely
contributing to long-term gene expression in developing mice.
Next, we used quantitative PCR (qPCR) to determine copy numbers
of mFIX in uninfected controls, Ad5-Cas9, and Ad5-Cas9-gRNA treated
mice (Fig. 4C). We also used qPCR to enumerate remaining viral gen-
omes by measuring the number of hexon copies remaining (Fig. 4C).
Hexon is the primary adenoviral capsid protein gene. In the Ad5-Cas9-
gRNA treated group, a signiﬁcant increase in mFIX copies was observed
compared to control Ad5-Cas9 treated animals. Of import, no sig-
niﬁcant diﬀerences in remaining viral genome copies were found.
To conduct a preliminary investigation into oﬀ-target integration
events, we utilized conventional Linear Ampliﬁcation Method-PCR
(LAM-PCR) to generate amplicons of sequences surrounding the mFIX
transgene. Most captured sequences from two Ad5-Cas9-gRNA treated
mice were derived from either the vector genome or potentially from
on-target integration (Supplemental Fig. 8). However, we also identi-
ﬁed a shared oﬀ-target integration site in chromosome 3
(RP24–555P13, Genebank ID AC115945.9) in both examined Ad5-
Cas9-gRNA treated mice. No obvious ROSA26-gRNA sequence
homology was found at the surrounding sequences, with the greatest
homology to the ROSA26-gRNA target sequence, without bp mismatch,
being 10 bp at a 20+ kb distance. Importantly, a NheI restriction site
was identiﬁed at the capture sequence validating the integration cap-
ture procedure (see Methods). Interestingly, the region in which the
integration event occurred is a retrotransposon element (RLTR11A)
(chr3:76541–77,051). Additionally, a second oﬀ-target integration site
was found in one animal occurring at the Gamma-Secretase-Activating
Protein (GSAP) (NM_001359876) locus (Chr5:21186363). Similar to the
other identiﬁed oﬀ-target site, a NcoI restriction site was present at the
capture sequence and no overt homology to the ROSA26-gRNA target
sequence was present (see Methods). Alignment of the primer used for
generation of linear amplicons did not have homology to sequences at
either oﬀ-target site, ruling out non-speciﬁc primer ampliﬁcation.
2.4. Therapy with Cas9-expressing vectors elicits anti-Ad5 and anti-Cas9
antibody production
Adenoviral vectors, as well as other viral vectors, have known im-
munogenicity and recent reports have highlighted potential im-
munogenicity of Cas9 [32–33]. Due to these reports, we asked if a
humoral response could be detected following adenoviral therapy.
Plasma taken from mice at 35 and 189 dpi showed an absence of IgG
antibodies against mFIX protein, whereas IgG antibodies speciﬁcally
reactive to the Cas9 endonuclease or to adenoviral particles were de-
tectable at both time points (Supplemental Fig. 9). Plasma from un-
treated mice showed no reactivity to any of these three components.
Thus, the clear presence of anti-Cas9 and anti-Ad5 antibodies shows a
humoral response was mounted against this therapeutic approach,
following exposure to vector and Cas9 transgene expression.
2.5. Therapy with Cas9-expressing vectors induces Cas9-speciﬁc T cell
responses and memory T cell formation
Having detected humoral responses to Cas9, we asked whether Cas9
elicits antigen-speciﬁc T cell responses in our therapeutic strategy. To
do so, we performed ex vivo restimulation of splenic T cells from mice
treated with adenoviral vectors or naïve controls. At 7 dpi, T cells from
Ad5-Cas9-gRNA treated mice produced IFN-γ upon stimulation with
antigen presenting cells (APCs) pulsed with recombinant Cas9 (rCas9)
or APCs treated with Ad5-Cas9-gRNA but not from untreated controls,
indicating that Cas9-speciﬁc naïve CD8+ T cell precursors were primed
in mice treated with Ad5-Cas9-gRNA (Fig. 5A and C). Additionally,
CD4+ T cells also produced IFN-γ in response to rCas9 antigen pre-
sentation (Fig. 5B and C). Similarly, Ad5-speciﬁc CD8+ T cells from
Ad5-Cas9-gRNA and Ad5-mFIX treated mice were detected at 7 dpi, as
determined by stimulation with Adpk-GFP treated APCs (Fig. 5A and C)
(Supplemental Fig. 10). The use of Adpk-GFP allows increased inter-
nalization by APCs compared to standard Ad5 vectors due to enhanced
transduction of APCs (Supplemental Fig. 11). Conversely, no mFIX-
speciﬁc T cells were detected following stimulation with APCs pulsed
with recombinant mFIX (rmFIX) (Fig. 5A–C). We also analyzed T cells
at 210 dpi and found that Cas9-speciﬁc and capsid-speciﬁc T cells
persisted, albeit at low levels (Supplemental Fig. 12). Boosting of mice
with adenoviral vectors at 200 dpi resulted in a small yet detectable
memory T cell response. In both contexts, T cells did not expand to
levels observed during the acute phase of treatment (Fig. 5). Given that
Cas9-speciﬁc T cells were still detectable well after initial treatment, we
asked if Cas9 may persist in vivo. To this end, we successfully PCR-
ampliﬁed an internal sequence of Cas9 coding sequence (CDS) from
liver extracted DNA in treated mice at 245 dpi (Supplemental Fig. 13).
The detection of Cas9 DNA at this late time conﬁrms a continued pre-
sence of the Cas9 transgene in treated mice. In summary, T cells from
treated mice displayed antigen-speciﬁc responses to Cas9 and viral
particles but not to mFIX. However, total elimination of Cas9 trans-
duced cells did not occur.
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2.6. In situ detection of mFIX and vector genomes conﬁrms persistent mFIX
expression and residual vector presence
As our gene knock-in strategy yielded long-term therapeutic protein
expression despite an immune response, we sought to conﬁrm the
presence of mFIX expression and residual vector genomes. In doing so,
we also observed diﬀerences in mFIX transgene and adenoviral genome
fates between knock-in (Ad5-Cas9-gRNA) and non-editing (Ad5-Cas9)
approaches. Using in situ hybridization permitted detection of mFIX
cDNA and RNA in both mFIX knock-in and non-editing treated mice at
245 dpi (Fig. 6A). Additionally, adenoviral genomes were detectable in
the nuclei of cells from these mice, independent and co-localized to
mFIX signal (Fig. 6A). These results support our current and previous
ﬁndings of continued gene expression and vector persistence [29]. The
use of positive control probes displayed signal in nearly all nuclei, while
negative control probes showed negligible signal (Supplemental
Fig. 14). Probes for mFIX showed ubiquitous detection in wild-type
C57Bl/6J liver sections and an absence of adenoviral genome detection
(Fig. 6A).
Blinded examination of nuclei displaying mFIX and/or adenoviral
genomic probe signals, from both knock-in and non-editing treated
mice (approximately 877 nuclei per mouse), suggested several trends
(Fig. 6B). A greater frequency of nuclear mFIX transgene or RNA was
seen among knock-in treated mice (1469 mFIX+ vs 1043 mFIX+ nu-
clei). Of note, the incidence of vector genome signal was potentially
higher in the nuclei of liver cells extracted from mice treated with non-
editing vectors (406 Ad5+ nuclei) compared to mice treated with
knock-in vectors (171 Ad5+ nuclei). Additionally, a greater incidence
of nuclear co-localization of mFIX and vector genomes was seen in non-
editing (279 co-localized nuclei) vs knock-in treatment (140 co-loca-
lized nuclei). These results suggested the possibility that integration-
containing mice retained the mFIX transgene dissimilarly than non-
editing treated mice, witnessed by the observed diﬀerences in co-lo-
calization, mFIX incidence, and vector genome detection.
3. Discussion
Long-term phenotypic correction is a primary objective of inherited
disease gene therapy. In general, early generation adenoviral vectors
have not been suitable to cure inherited diseases such as plasma deﬁ-
ciencies, due to the transience of therapeutic gene expression [34].
However, several studies have shown this vector can successfully treat
inherited disease in select contexts [35–37]. As a proof-of-principle, we
demonstrate that adenoviral vectors are capable of corrective gene
editing in pediatric inherited disease using a well-characterized disease
model, murine HB. In this regard, curative treatments of pediatric HB
and other inherited plasma deﬁciencies must embody methods to
overcome issues related to the application of gene therapy in juvenile
patients, including vector loss and high cell turnover in developing
organs [5]. Although generally considered as a transient vector, ade-
noviral vectors can persist in vivo with low levels of long-term expres-
sion [38–39]. The unique ability of adenoviral vectors to persist as
Fig. 5. Antigen-speciﬁc T cell responses to adenoviral-mediated gene editing therapy. (A) Mice were injected with PBS (untreated) (n=2), 1× 1011 viral particles
(VP) of Ad5-EF1α-mFIX (n=3) or Ad5-Cas9-gRNA (n=5) (columns). Seven days later, splenocytes were harvested and co-cultured under the indicated stimuli
conditions (rows). DC2.4 cells had been cultured prior with stimuli Adpk-GFP, Ad5-mFIX, rmFIX, Ad5-Cas9, or rCas9 allowing internalization, antigen processing and
presentation. IFNγ production by T cells was determined by ﬂow cytometry. Representative ﬂow plots of IFNγ production in CD8+ T cells are shown. (B) Splenocytes
from untreated or vector-treated mice were stimulated with DC2.4 cells treated with rmFIX or rCas9. Representative plots show IFNγ production in CD4+ T cells, as
determined by ﬂow cytometery. (C) Graph showing total quantiﬁcation of replicate ﬂow data, displaying IFNγ production in T cells (CD8+ T cells in left panel, CD4+
T cells in right panel) based upon DC2.4 antigen stimuli treatment (x-axis) and animal vector injection (colored bars). Statistical analysis was performed by unpaired
Student's t-test or one-way ANOVA followed by Tukey post-test. Error bars are the SEM. Results are from one animal experiment with two technical replicates.
Individual dots represent data from one animal.
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unintegrated episomes through cellular turnover make it an appropriate
tool to compare gene editing versus episomal-based approaches
[39–40]. In this study, direct comparison of episomal persistence to a
CRISPR/Cas9-mediated knock-in approach revealed that higher levels
of stable therapeutic protein expression can be achieved using targeted
integration. Importantly, mFIX knock-in treated mice expressed> 10%
normal FIX levels for nearly the duration of the experiment (averaging
76% at seven dpi to 8.4% normal FIX levels at 238 dpi), well within a
‘mild’ hemophilia phenotype, representing successful long-term protein
expression as the mice matured. Furthermore, the mFIX plasma con-
centrations of the mFIX knock-in group at 238 dpi (averaging 420 ng/
mL) was similar, or greater, than plasma mFIX levels in non-editing
treated mice at 35 dpi (averaging 350 ng/mL).
Increased FIX activity in terminal plasma samples from knock-in
compared to non-editing treatments supported the ﬁndings of the
ELISA. The non-editing vector approach provided low residual FIX ac-
tivity and only minor improvement over untreated mice, representing
minimal disease correction. In contrast, integration-based therapy sig-
niﬁcantly augmented FIX activity in mice, past maturation into adult-
hood, eﬀectively representing lifelong phenotypic correction [41].
Functional testing of the mice's bleeding diatheses also showed the
greatest therapeutic beneﬁt was provided by integration-based treat-
ment. As these three data were in strong agreement, we conclude in-
tegration-based treatment conferred an advantage in temporal main-
tenance of therapeutic protein expression and phenotypic correction
following adenoviral-mediated gene transfer in young animals.
As treatment with integration-capable vectors contributed to in-
creased therapeutic eﬃcacy, we sought to verify the presence of edited
ROSA26 alleles. Junction capture PCR conﬁrmed ROSA26 loci con-
tained errorless HDR-integrated mFIX cDNA, present in the livers of
treated mice even after 245 dpi. This ﬁnding indicated that edited cells
persist over a substantial time in vivo, editing machinery is active for a
continued period, or a combination of both situations occurred. For
example, cells edited early may have persisted over time, as hepato-
cytes are self-renewing, or editing may have occurred in other pro-
genitor cells [42]. Further evidence of edited cell persistence was the
observed increase in remaining mFIX copies at 245 dpi in Ad5-Cas9-
gRNA treated mice. The amount of residual viral genomes remaining in
mice at this time point was not signiﬁcantly diﬀerent, signifying vector
loss was equal between Ad5-Cas9 and Ad5-Cas9-gRNA groups. Thus,
the increase mFIX copies in Ad5-Cas9-gRNA compared to controls was
likely a result of transgene replication following integration in host
cells.
Although studies have posited long-term activity of CRISPR/Cas9 is
not evident in vivo, we detected the Cas9 gene at late time points,
suggesting CRISPR/Cas9 components may persist in animals longer
than expected when delivered as a transgene [43–45]. Relevant to this
supposition, an in vitro study demonstrated prolonged Cas9 activity
resulted in unintended editing outcomes [46]. Similarly, in our study,
junction capture PCR allowed identiﬁcation of unexpected mFIX-in-
tegrated ROSA26 alleles containing indels at the homology border, re-
sulting from scarred yet on-target cDNA knock-in. These error-con-
taining alleles show additional DNA repair mechanisms may occur with
CRISPR/Cas9 use in vivo, such as microhomology-mediated homologous
recombination and other non-canonical HDR pathways [47]. Another
potential explanation is an initial DSB was repaired by non-homologous
end joining (NHEJ) causing indels within sequences surrounding the
gRNA target site, but also correctly repaired the gRNA recognition se-
quence. A second DSB could then be repaired via HDR, resulting the
scarred insertion. To our knowledge, this is the ﬁrst report of on-target
insertions containing indels in vivo when using viral delivery of
CRISPR/Cas9 as a therapy. To reduce the chance for errors aﬀecting the
coding sequences of a therapeutic gene cassette, future HDR-based
approaches may seek to include large homology arms or insulating
sequences in the border regions of repair templates. Indeed, increasing
evidence of large deletions and complex genomic rearrangements
continues to be reported [48–49]. However, such ﬁndings are derived
from in vitro and zygotic injection experiments, both highly pro-
liferative contexts whereby DNA repair pathway activities likely diﬀer
compared to in vivo somatic gene editing.
Although we focused on characterizing on-target integrations, we
did perform a preliminary examination of oﬀ-target integrations. By
capturing sequences surrounding the mFIX expression cassette at 245
dpi in the livers of two mice, we surprisingly identiﬁed two oﬀ-target
integration sites (Supplemental Fig. 8). Interestingly, the oﬀ-target in-
tegration junctions appear to have occurred near the poly(A) regulatory
element and surrounding residual sequences from the cloning vector,
which may also impact future knock-in repair template designs.
However, the limitations of our LAM-PCR protocol use (i.e. clonal
analysis) is not a strictly quantitative method as it is dependent on two
nested PCRs, size-based ligation eﬃciencies, and the presence of re-
striction sites near integration sites. Of note, the ROSA26 target locus
does not have a nearby restriction enzyme site of the four enzymes we
used. Thus, the frequency of on-target versus oﬀ-target integration using
Fig. 6. In situ hybridization of mFIX RNA/DNA and
adenoviral vector genomes. (A) Liver sections from
mice treated with 7.5× 1010 viral particles (VP) of
Ad5-EF1α-mFIX and 2.5×1010 VP of either Ad5-
Cas9-gRNA (n=2) or Ad5-GFP (n=2), as well as
untreated C57Bl/6J (n=1), were used for in situ
hybridization at 245 dpi. Representative images
show hybridization of oligo probes targeting mFIX
RNA/DNA (red dots) and adenoviral DNA (blue
dots). Larger images are at 40× zoom, while insets
highlight nuclear-localized signals of mFIX RNA/
DNA (red dots/arrows) and vector genomic DNA
(blue dots/arrows) in individual cells. Scale bar is
20 μm. (B) Blinded analysis of 30 random liver sec-
tion images per group quantiﬁed mFIX (pink), ade-
noviral DNA (blue) or co-localized (gray) signals in
nuclei. Data is displayed as a percentage of total
detected nuclear signals. Percent of detected signals
are as follows: C57Bl/6J- 98.5% mFIX, 0.3% adeno-
viral genome, 1.1% co-localized signal; Ad5-Cas9-
gRNA treatment- 82.5% mFIX, 9.6% adenoviral
genome, 7.9% co-localized signal; Ad5-GFP treat-
ment- 60.4% mFIX, 23.5% adenoviral genome, 16.1% co-localized signal. Results are from three independent hybridization experiments. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Ad5-mediated delivery in vivo is not yet determined. As we were unable
to ﬁnd any evidence of homology to the gRNA target sequence at oﬀ-
target integration regions, the relationship between the use of CRISPR/
Cas9 editing and the oﬀ-target integration events is unclear.
Importantly, prior research using this ROSA26-targeting gRNA found
minimal oﬀ-target editing at top computationally-predicted sites and
the total identiﬁcation of oﬀ-target eﬀects is beyond the scope of this
proof of principle study [29]. Altogether, our examination of on- and
oﬀ-target integration sites have direct implications for gene editing
approaches that seek to use CRISPR/Cas9 for insertion, especially ap-
proaches targeting correction of small mutations or endogenous disease
loci.
Adenovirus is not considered to randomly integrate into host
chromosomes at an appreciable rate, however this topic has not been
re-examined recently and could explain observations of prolonged
persistence of vector genomes [28]. Although studies have observed
random adenoviral genome integration, the majority of adenoviral
persistence is believed to be a result of episome maintenance [40].
Thus, the residual persistent gene expression seen in our control groups
is likely the result of long-term maintenance of episomal viral genomes,
but we cannot currently exclude out the possibility of random viral
integration. Additionally, adenoviral episomes have a characterized
ability to persist through cell divisions, unlike other vectors such as
rAAV, a characteristic which may explain our prolonged detection of
adenoviral genomes and gene expression following application in
young animals [39–40].
Although persistent protein expression was observable in all treated
mice, albeit at diﬀerent levels, a common gradual reduction in ex-
pression suggested that certain mechanisms reduced expression. The
cause of expression loss following adenoviral-mediated gene transfer is
an area of intense study [39,50]. Several reports have highlighted the
impact of epigenetic silencing, immunological clearance, and cell
turnover on the loss of gene expression [50–53]. Knowing adenovirus
can elicit diverse immune responses, we focused on adaptive immune
responses to three components of our therapy: adenoviral particles,
Cas9 nuclease, and mFIX. We determined treated mice developed hu-
moral immunity against both Cas9 and the viral particles by 35 dpi,
persisting to at least 189 dpi (Supplemental Fig. 12). Although antibody
formation against adenoviral particles is well characterized, the for-
mation of anti-Cas9 IgG following a gene therapy has been described
infrequently in the context of the CRISPR/Cas9 system's extensive use
[30]. Additionally, recent publications have highlighted the presence of
anti-Cas9 antibodies in normal human populations, an important con-
sideration for clinical implementation of CRISPR/Cas9 [54–55]. Con-
sidering these ﬁndings, we assayed for antibody formation against the
mFIX protein, a major issue in hemophilia treatment, but did not detect
IgG-reactive to mFIX. The R333Q strain's circulating non-functional
human FIX (hFIX) may have permitted avoidance of a humoral response
against mFIX, due to self-tolerance of hFIX. These ﬁndings do not ex-
clude other potential classes of immunoglobulins which may have de-
veloped.
After identifying humoral responses against our therapy, we ex-
plored whether other adaptive immune responses occurred by mea-
suring antigen-speciﬁc T cell responses. As early as 7 dpi with adeno-
viral vectors expressing CRISPR/Cas9 components, a signiﬁcant
percentage of CD8+ and CD4+ T cells were speciﬁcally reactive to Cas9
and the viral particles. T cell-mediated IFNγ production from recogni-
tion of cognate capsid and Cas9 antigen was also detectable as late as
210 dpi, suggesting that adenoviral-mediated gene editing results in the
formation of memory T cells; this ﬁnding has direct implications for
repeat application of CRISPR/Cas9 therapies or use in people with
preexisting anti-Cas9 immunity. As both Cas9-speciﬁc CD8+ and CD4+
T cells were primed following adenoviral therapy, the antigen was
processed and presented via the major histocompatibility complex
(MHC) class I and MHC class II pathways in treated mice. However, the
relevant APC and mechanisms of T cell priming is yet undetermined.
Our demonstration of T cell-mediated IFNγ production in response
to Cas9 supports other recent studies ﬁnding immunological con-
sequences of CRISPR/Cas9 systems [32–32,54–57]. Similar results have
been found using human samples, however we identiﬁed antigen-spe-
ciﬁc T cell subsets, following a CRISPR/Cas9-based therapy. Taken to-
gether, we postulate these adaptive responses directly inﬂuenced the
observed protein expression proﬁles in our study. We also assume that
the induction of partial tolerance was possible, as the Cas9 gene per-
sisted and knock-in alleles were still detectable; therefore, all trans-
duced and edited cells were not eliminated. This theory is supported by
the ﬁndings that recombinant adenoviral vectors can induce an ex-
hausted T cell phenotype in vivo [58]. Furthermore, a balance of anti-
Cas9 eﬀector and regulatory T cells has been described in humans [59].
This recent publication illustrating Cas9 reactive T cells in humans has
direct relevance to our ﬁndings of CD8+ and CD4+ reactivity following
a therapeutic approach; together they imply that direct CRISPR/Cas9
use in humans will require strategies to mitigate immune activation
(e.g. immunosuppressive corticosteroids), strategies to induce tolerance
to Cas9 prior to treatment, or depletion of Cas9-reactive immune cells.
In our study, the ‘boosting’ of mice with additional vector did not ap-
pear to increase the magnitude of reactive T cells, and, importantly, did
not cause any lethality. Indeed, no mortality or overt signs of onco-
genesis was associated with the therapy in this study, consistent with
our prior ﬁndings [29]. The failure of ‘boost’ injections to recall
memory T cells was perhaps due anti-Ad5 antibodies, which can limit
transduction eﬃcacy [60]. However, we do not exclude the possibility
that other cells involved in innate immune responses, such as macro-
phage and NK cells, inﬂuenced mFIX expression [61]. In total, we posit
Cas9 is a challenge to clinical applications, due to its immunogenicity
derived from natural exposure and following a therapy [32]. Further-
more, we provide initial evidence that the Cas9 gene can persist in vivo,
a potential risk that must be fully elucidated by future studies. Thus,
future studies should explore methods to limit immune responses to
vector and gene editing components, determine vector inﬂuence, and
means to control spatial and temporal Cas9 activity.
Knowing vector treatment evoked cellular and humoral responses,
likely coinciding with inﬂammation and transient liver toxicity as re-
ported previously, we explored a potential means by which edited al-
leles persisted [53,61]. As mice were injected prior to maturation and
adenoviral vectors can induce substantial cell cycling due to liver re-
generation following vector-mediated toxicity, akin to partial hepa-
tectomies, we theorize appreciable cell cycling may have occurred post-
therapy [62]. The use of RNAscope technology allowed in situ ob-
servation of nuclear signals of mFIX DNA and RNA, as well as adeno-
viral episomes. The observations pointed towards a higher frequency of
mFIX nuclear signals and less co-localization to vector genomes in in-
tegration-mediating vector-treated mice consistent with our qPCR data.
In the context of a developing and regenerating liver, any cell that
underwent a mFIX integration event would replicate the integrated
transgene at every cell division. Such cellular turnover could theoreti-
cally support long-term maintenance of mFIX alleles and higher stable
protein expression, while avoiding silencing mechanisms which can
aﬀect episomal-based expression. This mechanism could also lead to a
dilution of vector genomes, as seen in our nuclear signal observations
and proposed in other reports [33]. In this study, we qualitatively show
knock-in versus non-editing treatment may result in diﬀerences of nu-
clear co-localization and transgene retention, an observation not in-
consistent with the above supposition.
Overall, we demonstrated adenoviral vectors are a suitable platform
for gene insertion in the context of diseased non-adult animals. By
treating in the adolescent stage, the risk of germline transmission of
transgene and vector sequences is reduced compared to prenatal and
intrauterine gene editing [19,63]. In this context, the early generation
Ad5-based vector used in this study would not likely be an optimal
choice for clinical application due to pre-formed immunity and its
known immunogenicity in humans. However, alternative non-human or
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rare serotype with reduced immune reactivity in humans may be sui-
table candidates for future gene editing approaches. Notably, adeno-
viral vectors can be rationally targeted; cell-speciﬁc delivery of gene
editing systems could be useful for diseases which arise from distinctive
cell types. Moreover, adenoviral vectors may be applicable to other
diseases requiring large cloning capacity, such as von Willebrand dis-
ease or hemophilia A using helper-dependent vectors devoid of viral
genes [25–26].
This study provides a critical proof-of-principle that a universal
gene editing platform is feasible for treating plasma deﬁciencies.
Importantly, complete cDNA knock-in at a safe harbor is potentially
applicable to all patients, regardless of causative mutations. Of note,
our correction of HB using gene knock-in is contrary to another study
reporting that adenoviral vectors are unsuitable for gene editing, due to
toxicity [64]. Our approach beneﬁted from episomal expression aug-
menting cDNA knock-in targeting a safe harbor locus. We do not target
the endogenous FIX locus, a context whereby NHEJ and other error-
prone DNA repair mechanisms induce new potentially deleterious
mutations [45]. Thus, we believe universal cDNA integration at a safe
harbor strategy has several advantages compared to correction of the
endogenous disease-causing gene. Targeting a single locus may yield
more consistent results and oﬀ-target eﬀects than targeting numerous
causative mutations with varying sequence composition and locus po-
sition. Thus, avoiding of the introduction of new mutations at the dis-
ease locus (occurring through NHEJ activity), applicability to numerous
diseases (rather than a disease-speciﬁc therapy tailored per mutation),
and production feasibility make safe harbor targeting a compelling
strategy. However, exceptions to this approach are diseases requiring
endogenous gene regulation (e.g. expressing the gene at speciﬁc times
during developmental processes) and diseases with dominant negative
mutations.
The increase in therapeutic eﬃcacy was modest in this study, en-
ough to have value in the context of hemophilia treatment. Comparison
of plasma levels achieved in this study to normal murine levels (normal
murine FIX plasma level is 2.5 μg/mL) might suggest greater correction
[65]. Additionally, the hemostatic eﬀect of our approach may be
greater in FIX null mice, due to a likely antagonism between the dys-
functional hFIX in the R333Q strain and the provided therapeutic mFIX.
In the future, optimized expression cassettes, stronger promoters, long-
lasting, and hyper-functional proteins can be applied to increase eﬃ-
cacy [66–67]. Improvements in HDR eﬃciencies and optimized editing
approaches, such as multiplexed targeted integrations, could also lead
to higher levels of therapeutic protein. Future studies should also assess
the risk of germline transmission to address if vectors reach gameto-
cytes and other critical preclinical studies to determine vector shedding,
further examination of vector persistence, and the possibility of vector
reactivation. Overall, we demonstrate that somatic gene editing for
pediatric plasma deﬁciencies can be standardized and is feasible with
viral vectors.
4. Conclusions
In summary, this proof-of-principle study shows a universal knock-
in approach can provide signiﬁcant improvements over non-editing
vector treatment by providing robust long-term phenotypic correction.
Notably, the use of adenoviral vectors may ﬁnd applications to treat
diseases that other vectors cannot, such as those constrained by
packaging capacity. We ﬁnd gene editing in vivo comprises on-target
knock-in through HDR but also from error-containing insertions, and
knock-in editing outcomes persists for a substantial time. Long-term
phenotypic correction was achieved using our straightforward ap-
proach, despite elicitation of B and T cell immune responses, supporting
the further development of editing-based strategies for treatment of
pediatric inherited plasma deﬁciencies. We highlight that therapeutics
involving CRISPR/Cas9 are certainly viable, but preclinical studies
should recognize and address potential immune and genetic
consequences that may occur post-treatment.
5. Methods
5.1. AdV5 vector constructions
The adenoviral vectors Ad5-Cas9-gRNA, Ad5-Cas9, and Ad5-gRNA
were constructed as described previously (Fig. 1) [29]. A HDR template
vector, was generated expressing mouse FIX (mFIX) cDNA. First, mFIX
was digested from plasmid pGem-mFIX (Sinobiologicals, Beijing,
China) using ZraI and Eco53kI. The pBapoEF1α plasmid (Clontech La-
boratories, Mountain View, CA) was digested with BamHI and HindIII,
then Klenow-fragment and calf-alkaline phosphatase treated. The mFIX
cDNA was sub-cloned into pBapoEF1α for expression control by the
human EF1α promoter and HSV-TK polyadenylation transcription ter-
minator. Sequencing conﬁrmed correct orientation, resulting plasmid
pBapoEF1α-mFIX. The expression cassette was restricted using ClaI,
Klenow-fragment treated, and ligated into the PmeI site of a ROSA26
HDR repair template plasmid, provided by the Genome Engineering and
iPSC Center at Washington University School of Medicine (WUSM).
This plasmid, pROSA26, contains ~800 bp of sequences homologous to
the ROSA26 locus, ﬂanking the gRNA target site [29]. In this targeting
repair template, the ROSA26 gRNA does not cut the template as the
gRNA target sequence is mutated by the insertion of a multiple-cloning
site, eﬀectively abolishing gRNA recognition. pROSA26-EF1α-mFIX
digestion with PvuII generated a fragment containing homology se-
quences and the mFIX expression cassette for ligation into the EcoRV
site of pShuttle (Agilent Technologies, Santa Clara, CA), an adenoviral
E1-region shuttle plasmid (lacking any promoter), making pShuttle-
EF1α-mFIX-ROSA26. Following linearization with PmeI, this shuttle
plasmid was recombined into the E1-deleted region of pAdEasy-1
plasmid (human adenovirus C serotype 5 [Ad5] genomic plasmid)
(Agilent Technologies) in Escherichia coli (E. coli) BJ5183, to generate
pAd-EF1α-mFIX (Fig. 1). All restriction enzymes and nucleases were
purchased from New England Biolabs (Ipswich, MA).
Additional control vectors were constructed similarly but lack any
ROSA26 homology sequences or CRISPR/Cas9 genes (Supplemental
Fig. 10). Brieﬂy, the mFIX cDNA fragment was inserted into pShuttle-
CMV (Agilent Technologies) at the EcoRV site, under control of the
CMV promoter, and recombined into pAdEasy-1, generating pAd-CMV-
mFIX. Additionally, previously described Adpk-EGFP, which contains a
modiﬁed capsid generated by replacement of the Ad5 ﬁber knob with
porcine adenovirus-4 ﬁber knob resulting in increased DC2.4 trans-
duction, and Ad5-EGFP were also used (Supplemental Fig. 11) [68–69].
5.2. Tissue culture
Human embryonic kidney 293 (HEK-293) cells (Microbix
Biosystems Inc. Mississauga, Ontario, Canada), BNL 1NG A.2 (ATCC,
Manassas, VA), and A549 cells (ATCC) were cultured in DMEM-F12 Mix
(Lonza-BioWhittaker, Basel, Switzerland) with 10% or 2% FBS (Sigma-
Aldrich, St. Louis, MO). The dendritic cell line DC2.4 cells were a kind
gift from Dr. Kenneth Rock (University of Massachusetts Medical
School) and primary splenocytes were incubated in RPMI media
(Sigma-Aldrich) supplemented with 10% FBS. Cell culture was per-
formed in sterile conditions and cells incubated at 37 °C in an atmo-
sphere of 5.0% CO2.
6. Adenovirus production
Viral generation was performed using standard techniques [70].
Brieﬂy, adenoviral genome-containing plasmids were digested with
PacI releasing the recombinant viral genomes, for transfection into
HEK-293 cells. After rescue and serial ampliﬁcation, viruses were pur-
iﬁed through ultra-centrifugation in cesium chloride gradients. Partial
sequencing of puriﬁed virus genomes conﬁrmed vector constructs.
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Expression of vector-encoded transgenes was conﬁrmed via Western
blot (data not shown). Titrations on replication-restricted A549 cells
veriﬁed absence of replication-competent adenoviral (RCA) con-
tamination. Gene editing knock-in with Ad5-Cas9-gRNA and isogenic
donor vectors, encoding other transgenes in the exact conﬁguration of
Ad5-EF1α-mFIX, have been reported [29].
6.1. In vitro Indel formation assay
The immortalized murine BNL-1NG A.2 cell line was seeded at
5× 105 cells per well on six well plates and grown to conﬂuency. One
well per plate was harvested and cells counted. Next, PBS, 2×103 VP,
4× 103 VP, 8×103 VP, or 12×103 VP of Ad5-Cas9-gRNA or Ad5-
Cas9 were added to individual wells. 96 h later, cells were harvested
and submitted for Illumina targeted deep sequencing of the ROSA26
locus. The results are from two independent experiments.
6.2. Animal studies
A murine model of HB, referred to as R333Q strain, was maintained
as a homozygous inbred colony. This strain was previously generated
by the knock-in of defective hFIX cDNA (containing an R to Q missense
mutation at the FIX catalytic domain eﬀecting FIXa/FVIIIa binding)
into the endogenous mFIX locus in a C57Bl/6J background [71]. Thus,
R333Q mice express a missense non-functional hFIX variant (less
than<1% FIX activity) and no mFIX. This model recapitulates most
human HB cases whereby circulating FIX is present (~70% of cases) yet
has reduced or absent function. R333Q genotype was conﬁrmed using
primers (Table 2) (Primers 1–2) for the neomycin (neo) gene residing
within the hFIX insertion cassette. Further genotyping ensured the ab-
sence of wild-type murine FIX with a forward primer (Primer 3) located
in intron 1 region and a reverse primer in intron 2 of Mﬁx (Primer 4)
(Supplemental Fig. 15). C57Bl/6J mice (Jackson Laboratory, Bar
Harbor, ME) served as wild-type controls. Male and female mice were
used in all groups throughout the study. In humans, HB is X-linked and
mostly aﬀects males. However, the use of a single sex in animal studies
can introduce sex-based bias, including gene therapy studies [72]. In-
clusion of both genders potentially diminishes such bias and allows
extrapolation of results to other plasma deﬁciencies aﬀecting both
males and females.
Four weeks old R333Q hemophilia mice were tail vein injected with
7.5×1010 viral particles (VP) Ad5-EF1α-mFIX and 2.5×1010 VP of
either Ad5-Cas9-gRNA (n=9) or Ad5-Cas9 (n=7) in PBS solution.
Blood was collected approximately biweekly from the submandibular
vein into heparin-coated capillaries (Thermo Fisher Scientiﬁc,
Waltham, MA) for ELISA quantiﬁcation of mFIX. Heparinized blood was
centrifuged, plasma aliquoted, and stored at −80 °C until use. Prior to
injection, a limit of at least 20% normal FIX level at the initial time
point was set as a requirement for inclusion in the temporal gene ex-
pression experiment, along with optimal injection noted at time of viral
administration. Plasmas for mFIX enzymatic assays were collected into
an approximate 1:9 volume ratio of 3.8% sodium citrate (Sigma-
Aldrich) to blood. Citrated blood was collected from the tail vein during
the tail clip assay (245 dpi) and separately from submandibular vein
(238 dpi), a week prior to tail clip.
6.3. mFIX ELISA
An optimized sandwich ELISA was developed using aﬃnity-puriﬁed
anti-mFIX polyclonal antibodies (Cat. # 442404, Lot 1,194,200)
(Sinobiologicals). MaxiSorp polystyrene 96-well plates (Thermo Fisher
Scientiﬁc) were coated with 2.0 μg/mL primary capture antibodies in
sodium carbonate buﬀer [pH 8.5] (Corning Inc., Corning, NY) and
stored at 4 °C. Plates were blocked with 2.5% BSA (Santa Cruz
Biotechnology, Dallas, TX) in PBS and 0.05% Tween 20 (Sigma-
Aldrich). Washes were performed with 0.05% Tween 20 in PBS. All
samples, detection antibodies, and standards were diluted in HiSpec
Diluent (Bio-Rad Laboratories, Hercules, CA) spiked with pooled mFIX-
deﬁcient plasma from untreated R333Q hemophilia mice. Secondary
antibody was generated by HRP-conjugation (SeraCare, Milford, MA) of
the capture antibody and used for detection at 2.5 μg/mL. Chromogenic
development using 3,3′,5,5’-Tetramethylbenzidine (TMB) (Sigma-
Aldrich) followed by acidic stop solution (Invitrogen, Carlsbad, CA)
allowed reading of OD values at 450 nm.
Serially diluted recombinant mFIX (Sinobiologicals), ranging
62.5 ng/mL to 3.906 ng/mL, was used on each plate to generate a
Table 2
A list of oligonucleotide primer sequences and their corresponding application in this study is provided.
Primer details
Primer number Sequence Use
1 FWD-5′- TGCTCCTGCCGAGAAAGTATCCATCATGGC-3′ R333Q Genotyping





5 FWD-5′-CCGTGAAGGAGGCAAAGATTCG-3′ mFIX Junction Capture PCR
6 REV- 5′-AAGCTCACAAGACCTTAGGTCAGGAAAGAC-3′ mFIX Junction Capture PCR
7 FWD 5′- CGTACGAGGAGGCACTAAAGC-3′ Hexon Ampliﬁcation







12 FWD-5′-CCGTGAAGGAGGCAAAGATTCG-3′ First Nested PCR
13 REV-5′-CTGAAGGCTCAGGTTACACAGGCAC-3′ First Nested PCR
14 FWD-5′-GTGTTGGGTCGTTTGTTCATAAACGC-3′ Second Nested PCR
15 REV-5′-GCTCGTAGGAGGTGTTCCAGTTCACC-3′ Second Nested PCR
16 FWD-5′-GCGAGAACCAGACCACCC-3′ Cas9 CDS
Ampliﬁcation
17 REV-5′-CGAGTTATTAGGCGTAGTCGGGCA-3′ Cas9 CDS
Ampliﬁcation
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standard curve for calculation of sample mFIX concentrations
(Supplemental Fig. 16). mFIX concentrations in plasma samples were
calculated from OD values within the linear range of the standard curve
and at least twice the standard deviation of the zero value. Cross-re-
activity to hFIX was minimal and only detectable at very low sample
dilutions using this ELISA system. To control for detection due to the
minor cross-reactivity, plasma from untreated R333Q mice was diluted
at the same ratio as treated samples. These control dilutions were used
to calculate if background was detected from cross-reactivity to the
circulating non-functional hFIX (of the R333Q strain) on each plate.
Any detection from control animals' plasma background was subtracted
from sample values at the corresponding dilution. Bona ﬁde detection of
mFIX was conﬁrmed by measuring OD 450 nm values of plasma dilu-
tions seven days prior and seven dpi with Ad5-EF1α-mFIX
(Supplemental Fig. 1). All plasma samples were run at multiple dilu-
tions in duplicate and time points repeated. Total ELISA results are from
two independent animal experiments.
6.4. mFIX enzymatic activity assay
An enzymatic assay (Aniara Diagnostica, West Chester, Ohio) was
used to measure mFIX activity in plasma of treated and un-treated mice.
The assay consists of a puriﬁed protein cascade with a chromogenic
readout. Brieﬂy, puriﬁed phospholipids, calcium and activated FXI are
provided to activate mFIX within the plasma samples, generating
mFIXa. Then, the supplied thrombin-activated FVIII (FVIIIa) en-
zymatically complexes with FIXa activating FX. FXa hydrolyzes the
chromogenic substrate, freeing paranitroaniline (pNA). The amount of
pNA released is measured by absorbance at 405 nm and is directly
proportional to the concentration of FIX in the sample. A standard curve
was generated using serially diluted pooled plasma from C57Bl/6J mice
diluted into pooled mFIX deﬁcient plasma (R333Q sourced). The assay
procedure was performed according to manufacturer's instructions.
Negative controls consisted of untreated R333Q animals (n=11),
while positive controls consisted of untreated C57Bl/6J mice (n=10).
All samples were diluted into diluent spiked with pooled mFIX-deﬁcient
plasma. Samples were tested at dilutions from 1:5 to 1:20, with all
samples being tested at one dilution per test. Standard curve ranged
from 0.5% to 20% normal mFIX activity. Plasma from the sub-
mandibular vein and tail vein were analyzed separately and FIX ac-
tivities measured in each mouse averaged. Results shown are from three
independent tests.
6.5. Tail clip assay for functional correction
To assay animals' ability to control bleeding following an injury, a
terminal tail clip approach was used. 245 days after injection, treated
and untreated mice's tails were clipped at a diameter of 2.0 mm. The
clipped tail was intermittently dabbed onto ﬁlter paper and the time
until bleeding stopped was measured. The bleeding assay was termi-
nated at 30min to limit animal suﬀering and participation time.
Positive controls consisted of wild-type C57Bl/6J mice (n=9), while
untreated R333Q hemophilia B mice (n=9) were used as negative
controls.
6.6. Junction capture PCR of mFIX-integrated ROSA26 alleles
DNA extraction from homogenized liver tissue was performed by
incubation at 55 °C for several hours in the presence of 1.0% SDS
(Sigma-Aldrich), RNaseA (GE Healthcare, Chicago, IL) and proteinase K
(Thermo Fisher Scientiﬁc). DNA was puriﬁed through phenol/chloro-
form extraction and precipitation with 100% ethanol (Thermo Fisher
Scientiﬁc) and 3M sodium acetate [pH 5.2] (Thermo Fisher Scientiﬁc).
DNA concentration was calculated using an absorbance value of 1.0 at
260 nm being equivalent to 50 μg/mL of DNA and the quality of DNA
checked on agarose gel.
To validate gene editing and targeted integration, ampliﬁcation of
the 3′-end of ROSA26 alleles containing integrated-mFIX was performed
using liver extracted DNA. One primer binding within mFIX cDNA
(Primer 5) and a second primer (Primer 6) binding in the genomic re-
gion of ROSA26 (past the homology border) ampliﬁed the integration
junction. PCR reactions consisted of 5× PhireII buﬀer, dNTPs (Thermo
Fisher Scientiﬁc), primers (5 μM), 350 ng of DNA template, and 0.5 μL
of PhireII polymerase (Thermo Fisher Scientiﬁc). Primers were an-
nealed at 69 °C and amplicons visualized on agarose gels by ethidium
bromide staining. Results shown are representative of four independent
PCRs. Amplicons were gel-extracted and Sanger sequenced, conﬁrming
genomic origin and targeted integration. Loading control consisted of
ampliﬁcation of a 619-bp fragment of the adenoviral gene hexon using
two primers (Primers 7–8).
6.7. Quantiﬁcation of mFIX and hexon copies using qPCR
qPCR reactions and cycling were performed as described in detail
elsewhere [29]. Brieﬂy, a standard curve for m-Actin was generated
using serial dilutions of optically pure genomic DNA from an untreated
C57Bl/6J mouse and the assumption that one copy of m-actin is present
in the mouse genome of 2.8×109 bps. The second standard curve was
generated using serial dilutions of the vector plasmid pAd5-EF1α-mFIX,
which contains one copy of mFIX cDNA and hexon. A commercial
primer pair and hydrolysis probe (conjugated to 6-carboxyﬂuorescein
[6-FAM]) speciﬁc for mFIX (spanning an exon/exon junction)
(mm01302526_m1, Thermo Fisher Scientiﬁc) or a primer/probe for
hexon, described elsewhere, were used in separate reactions to quantify
copy numbers of each. In each reaction a separate [VIC]-conjugated
probe and primer pair speciﬁc for m-actin DNA (mm00607939, Thermo
Fisher Scientiﬁc) was included to normalize copy numbers. Each mouse
sample was run in duplicate and the results shown are averaged from
two independent qPCRs.
6.8. LAM-PCR to capture oﬀ-target integrations
LAM-PCR was performed essentially as described in detail else-
where [17,73]. In brief, a biotinylated primer (Primer 9) spanning an
exon/exon junction (to avoid priming to the portions of endogenous
mFIX gene intact in the R333Q model) and speciﬁc to mFIX cDNA was
used to generate linear ssDNA amplicons of surrounding sequences
from whole liver DNA of two mice injected with 7.5×1010 VP of Ad5-
EF1α-mFIX. Following second strand synthesis, amplicons were di-
gested with NheI, AvrII, XbaI, and NcoI and ligated to linkers with
corresponding sticky ends. Linkers were produced as described else-
where, with the NcoI linker being described previously [17,29,73].
However, the novel linker compatible to NheI, AvrII, and XbaI over-
hangs sequences are provided (Primers 10–11). Using the known se-
quences of the ligated linker, two nested PCRs were performed (Primers
12–13, Primers 14–15). PCR amplicons were then puriﬁed, blunt end
cloned into the pCR-XL-2-TOPO plasmid (Thermo Fisher Scientiﬁc) and
transformed into OmniMAX-2-T1R E. coli (Thermo Fisher Scientiﬁc). 14
clones were analyzed by Sanger sequencing and BLAST aligned to de-
termine sequences surrounding the mFIX cDNA [74]. Results are from
one LAM-PCR preparation and six independent nested PCR prepara-
tions.
6.9. PCR ampliﬁcation of the Cas9 gene
A 2.0-kb internal sequence of Cas9 was PCR-ampliﬁed from liver
extracted DNA using two primers (primers 16–17). Results shown are
representative from two independent PCRs. Positive controls consisted
of the pAd-Cas9-gRNA plasmid, used for viral generation, and liver
extracted DNA taken 3 dpi with 1×1011 VP of Ad5-Cas9-gRNA.
Negative controls consisted of the unmodiﬁed parental pAd-Easy1
plasmid and liver DNA of an untreated R333Q mouse. Loading controls
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consisted of ampliﬁcation of a 619-bp fragment of hexon.
6.10. Assay for antibody formation against adenovirus, Cas9, or mFIX
Recombinant mFIX (Sinobiologicals), recombinant spCas9 (rCas9)
(PNA Bio Inc., Thousand Oaks, CA), or empty adenovirus particles were
immobilized on MaxiSorp 96-well plates at 50 ng/well in carbonate
coating buﬀer overnight at 4 °C. Adenoviral particle mass was estimated
using the MW of an adenoviral particle as 150×106 Da [75]. Plates
were blocked with PBS containing 2.5% BSA and 0.5% Tween 20.
Plasma samples were sourced from untreated mice (n=3), mice
treated with Ad5-EF1α-mFIX and either Ad5-Cas9 (n=4 for rCas9 and
capsid, n=5 for rmFIX) or Ad5-Cas9-gRNA (n=4 for rCas9 and Ad5
capsid, n=6 for rmFIX). Plasma was obtained from mice at 35 and 189
dpi and diluted into HiSpec Diluent spiked with pooled untreated
R333Q plasma. Plasma dilutions were incubated in duplicate on the
protein coated plate. Wells were washed and 0.5 μg/mL of polyclonal
goat anti-mouse-IgGs HRP-conjugated antibody (Cat# P0447, Agilent
Technologies) was applied to detect the presence of plasma IgG anti-
bodies speciﬁcally reactive to proteins coating the wells. Detection of
the secondary antibody was performed using TMB for OD measure-
ments at 450 nm. Positive control for viral particle coating and detec-
tion was a murine antibody raised against adenoviral capsid ﬁber
protein (clone 4D2, Thermo Fisher Scientiﬁc). Positive control for rCas9
coating was a polyclonal rabbit anti-Cas9 antibody (Cat# 632607, Ta-
kara Bio Inc., Shiga, Japan) detected with HRP-conjugated goat anti-
rabbit IgG (Cat# P0448, Agilent Technologies). Recombinant mFIX
coating was positively conﬁrmed using direct detection with an HRP-
conjugated anti-mFIX antibody (Cat# 79804, GeneTex Inc., Irvine, CA).
Additional assay functionality was validated by the immobilization of
His-tagged alpha1-antitrypsin protein (Sinobiologicals), followed by
recognition with monoclonal anti-His-tag murine IgG (Cat# 34670,
Qaigen, Hilden, Germany) and detection by the same goat anti-mouse
IgG-HRP antibody used for the plasma sample IgG detection. Negative
controls consisted of untreated mouse plasma, wells incubated without
secondary detection antibody, and wells without plasma incubation.
Results are from two independent test with all samples in duplicate.
6.11. Stimulation assays for antigen-speciﬁc T cell responses
Antigen-speciﬁc T cell responses were assayed by ex vivo restimu-
lation as previously described [76]. Seven days prior to the assay,
10 weeks old R333Q hemophilia B mice were injected with either PBS
(naive control, n=2), 1× 1011 VP of Ad5-Cas9-gRNA (n=5) or Ad5-
EF1α-mFIX (n=3). Three dpi, two replicate 96-well plates (Techno
Plastic Products AG, Trasadingen, Switzerland) were seeded with
9× 104 DC2.4 cells per well. The next day DC2.4 cells were transduced
with 2000 VP/cell of either: Adpk-GFP (an Ad5 vector with the knob
portion of the ﬁber capsid protein replaced with porcine adenovirus 4
ﬁber knob permitting strong DC2.4 transduction), Ad5-mFIX, or Ad5-
Cas9 (Supplemental Figs. 10–11) [68]. Separately, DC2.4 cells were fed
10 μg/mL rCas9 or 7 μg/mL rmFIX. Seven dpi mice were sacriﬁced,
spleens harvested, and cells ground through a 70-μm cell strainer. RBCs
were lysed and 1× 106 splenocytes plated into wells containing the
DCs of above stimuli treatments. Splenocytes and treated DC2.4 cells
were co-cultured for one hour at 37 °C to allow stimulation and signal
transmission. After one hour, cells were incubated with Golgi plug
(Becton Dickinson Biosciences, Franklin Lakes, NJ) for three hours at
37 °C to block secretion of IFN-γ. Cells were then stained for the fol-
lowing: Viability Dye eFlour 506 (eBioscience, San Diego, CA) and
antibodies for CD3 (clone 145-2C11, eBioscience), CD4 (clone RM4–5,
Invitrogen), and CD8 (clone 53–6.7, eBiosciences) diluted in Fc Block
(Becton Dickinson Biosciences). Cells were washed again, ﬁxed and
permeabilized using the BD Cytoﬁx/Cytoperm kit (eBioscience), and
stained for intracellular IFN-γ (clone XMG1.2, eBioscience). Experi-
mental controls were splenocytes from naïve mice co-cultured with the
above stimuli treatments. Results are obtained from one animal ex-
periment with multiple biological replicates and with two technical
replicate assays.
A stimulation assay for memory T cell formation was performed as
described above, only diﬀering by the time post-injection that spleno-
cytes were harvested. In this experiment, mice excluded from the ELISA
time course experiment, due to incomplete/unacceptable injection and
low initial FIX levels (< 20% normal, see ‘Animal Experiments’), were
used at 210 dpi. Although precluded from the ELISA expression time
course, vector exposure in these animals was conﬁrmed by detection of
low levels of transgene expression. To increase exposure to vector and
vector-encoded transgenes, and potentially induce memory T cell recall
responses, a portion of these mice were ‘boosted’ with a second virus
injection seven days before the T cell stimulation assay. Groups con-
sisted of mice exposed to PBS (naïve, n=1), Ad5-Cas9-gRNA (boosted
n=3, un-boosted n=2) or Ad5-gRNA (boosted n=1, un-boosted
n=1). ‘Boost’ injections consisted of tail vein injection of 5.5× 1010
VP/mouse. DC2.4 cells were transduced with 2000 VP/cell of either
Adpk-GFP, Ad5-Cas9, or Ad5-gRNA. Separately, other DCs were fed
10 μg/mL recombinant Cas9 protein. Assay procedure and data analysis
were performed as described above. Results are from one animal ex-
periment with multiple biological replicates and with two technical
replicate assays.
6.12. In situ hybridization of mFIX RNA/DNA and adenoviral DNA
Liver tissue was harvested from R333Q mice tail vein injected with
7.5×1010 VP of Ad5-EF1α-mFIX and either 2.5× 1010 VP of Ad5-
Cas9-gRNA (n=2) or 2.5× 1010 VP Ad5-GFP (n=2) at 245 dpi
(Supplemental Fig. 10). Mice were whole body perfused with 10%
neutral buﬀered formalin in PBS, livers harvested and dissected, then
ﬁxed overnight at 4 °C. Next, the tissue was sequentially stored at 4 °C
in 10%, 20%, and 30% sucrose solutions (Sigma-Aldrich) with over-
night incubations in each solution concentration. Next the tissue was
embedded in NEG-50 (Thermo Fisher Scientiﬁc) freezing media, then
ﬂash frozen using 2-methyl butane (Sigma-Aldrich) and liquid nitrogen.
Tissue was sliced into 9-μm sections, placed on slides, and stored de-
siccated at −80 °C.
In situ identiﬁcation of mFIX RNA and DNA, as well as adenoviral
genomic DNA, was accomplished using oligonucleotide probes
(Advanced Cell Diagnostics Inc., Newark, CA). Brieﬂy, a series of 18- to
25-nt ‘anti-sense’ probes (approximately 20 oligonucleotides) were
designed to tile across a 1.0-kb region of mFIX cDNA (nt: 401–1699)
and mRNA. To detect adenoviral genomic DNA, ‘sense’ probes targeted
a 1.0-kb region (nt: 26,389–27,424 of pAd-Easy1) of the adenovirus
genome. Following cognate probe recognition and hybridization to a
target molecule, a series of ampliﬁcation steps were performed using
ampliﬁer probes speciﬁc to the target probe, according to manufac-
turer's protocol. Speciﬁcity is ensured by the assay's signal ampliﬁcation
premise, which requires at least two side-by-side target probes to be
hybridized to a target molecule before the signal can be ampliﬁed for
detection [77]. Chromogenic detection of mFIX DNA and RNA mole-
cules resulted as red punctuate dots, while adenoviral DNA was de-
tected as blue punctuate dots. Slides were counterstained with hema-
toxylin solution (Sigma-Aldrich) to stain nuclei. To ensure probe
hybridization to DNA, a brief denaturation at 65 °C followed by over-
night hybridization at 40 °C was performed [78]. DNA detection was
separately conﬁrmed by detection of signals on slides treated with
RNaseA/T1 solution (Thermo Fisher Scientiﬁc). Liver sections from an
untreated C57Bl/6J mouse served as a positive control for mFIX DNA
and RNA recognition. Controls probes consisted of 2-plex negative
probes targeting the bacterial gene dapB (one probe per detection
channel), while positive probes recognized murine PPIB and POLR2A.
Slides were observed and imaged using bright ﬁeld microscopy.
Thirty random images of liver sections from treated mice at 40×
magniﬁcation were chosen for analysis of nuclear signals of mFIX RNA/
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DNA and adenoviral genomic DNA. Additional images for analysis in-
cluded liver sections of a C57Bl/6J mouse and treated mice hybridized
with negative and positive control probes. Slide images were from three
independent hybridization experiments. Images were randomized and
blinded for unbiased quantiﬁcation of nuclei containing red mFIX
signal, blue adenoviral genome signal, or co-localization of both sig-
nals.
6.13. Statistics
ELISA statistical analysis was performed by comparing groups at
each individual time-point. To perform parametric testing, an F-test
determined whether the groups' samples had equal variance. If equal
variance was determined, a Student's t-test was used. For data with
signiﬁcantly unequal variance, a heteroskedastic t-test was used. To test
for signiﬁcance without the assumption of normal distribution, data
was submitted to non-parametric Mann-Whitney U test. Data was only
deemed signiﬁcant if both parametric and non-parametric tests were in
agreement. Testing was performed using the Real Stats Software
package in Microsoft Excel (http://www.real-statistics.com/free-
download/).
Statistical analysis of ﬂow cytometry data was performed with un-
paired Student t-test or one-way ANOVA followed by Tukey post-test
comparison. All other statistical analysis was performed using
GraphPad PRISM software. First, each groups' data was tested for a
normal distribution using a D'Agostino Pearson Test or Shapiro-Wilk
Test (if ‘n’ was too small for D'Agostino Pearson testing). Normally
distributed data was used in parametric unpaired t-tests to compare
groups. If groups had equal variance (determined via F-test) an un-
paired Student's t-test was used. If groups had signiﬁcantly diﬀerent
variance an unpaired t-test with Welch's correction was used. For
comparison of non-normally distributed data, non-parametric Mann-
Whitney U test was performed. All t-tests were two-tailed. For all sta-
tistical analyses p-values were denoted as> 0.05 (no signiﬁcance
[ns]), < 0.05 (*),< 0.01 (**), or< 0.001 (***).
6.14. Study approval
Animals were housed in pathogen free conditions with access to
food and water ad libitum under guidelines and care of the Department
of Comparative Medicine at WUSM. The WUSM animal management
program is American Association for the Accreditation of Laboratory
Animal Care accredited, and meets NIH Guide for the Care and Use of
Laboratory Animals standards. All animal experiments were performed
in accordance to an IACUC approved protocol (#201510191).
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